Every 10-Q that VYNE Therapeutics Inc. (VYNE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VYNE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYNE filings page.
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reports that for the six months ended June 30, 2026 it generated $0.2 million in royalty revenue and incurred a net loss of $6.6 million, a substantial reduction from $14.4 million a year earlier, primarily due to sharply lower research and development spending as legacy programs were wound down ahead of its merger with Yarrow.
Cash and cash equivalents were $22.9 million and total assets $23.6 million, with liabilities of only $1.5 million, leaving stockholders’ equity at $22.1 million as of June 30, 2026 and no debt outstanding. The company completed a strategic merger with privately held Yarrow, changed its name, effected a 1‑for‑50 reverse stock split, declared a pre‑closing $17.3 million special cash dividend, and increased authorized common shares to support its new clinical‑stage focus on YB‑101 for Graves’ disease and thyroid eye disease. Management states that, giving effect to the merger, existing cash is expected to fund operations for at least 12 months from the financial statement issuance date, and Finacea royalty revenues are expected to cease after December 31, 2026 following LEO Pharma’s license termination.
VYNE Therapeutics reported Q1 2026 royalty revenue of $0.1 million, down from $0.2 million a year earlier, and cut research and development spending to $0.8 million from $6.1 million as it winds down its BET inhibitor programs ahead of a planned merger with Yarrow Bioscience.
Net loss narrowed to $3.6 million from $8.6 million, helped by lower R&D. Cash, cash equivalents and marketable securities totaled $24.9 million with no debt as of March 31, 2026, and stockholders’ equity was $24.6 million.
The company has agreed to merge with privately held Yarrow, which has already raised $100 million in Series A preferred stock and secured about $100 million in additional pre-closing financing commitments. Before closing, VYNE expects to pay a special cash dividend of roughly $14.5–$16.5 million in total to existing stockholders. Management believes current liquidity is sufficient through the anticipated Q3 2026 closing and for at least 12 months from the reporting date.
VYNE Therapeutics reported Q3 results reflecting a clinical-stage pivot and tighter spending. Royalty revenues were $169 thousand, while operating expenses fell to $8.0 million from $13.2 million a year ago, yielding an operating loss of $7.8 million and a net loss of $7.3 million. For the nine months, net loss was $21.6 million.
Liquidity remained stable with $32.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, no debt, and total assets of $36.1 million. Operating cash use was $29.4 million year‑to‑date; management believes existing resources fund operations for at least 12 months, and cost reductions are expected to extend runway into the first half of 2027.
Pipeline updates: the FDA imposed a partial clinical hold on VYN202 in April; dosing for females at two doses resumed in June, with a 12‑week dog toxicology study initiated to address male enrollment. VYNE terminated the Phase 1b psoriasis trial after unblinding seven subjects showed directional improvements and plans to advance VYN202 in other immune‑mediated diseases. The Phase 2b repibresib (VYN201) vitiligo study did not meet primary and key secondary endpoints; VYNE is seeking a partner. A strategic review, including potential partnerships or transactions, is ongoing.